# EDGAR Filing Document

**Accession Number:** 0001100682
**File Stem:** 0001100682-26-000020
**Filing Date:** 2026-2
**Character Count:** 84491
**Document Hash:** 93230dc55d4fbe62686eb91dc30973be
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001100682-26-000020.hdr.sgml**: 20260218

**ACCESSION NUMBER**: 0001100682-26-000020

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260218

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260218

**DATE AS OF CHANGE**: 20260218

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- **CENTRAL INDEX KEY:** 0001100682
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 061397316
- **FISCAL YEAR END:** 1227

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15943
- **FILM NUMBER:** 26645409

**BUSINESS ADDRESS:**
- **STREET 1:** 251 BALLARDVALE ST
- **CITY:** WILMINGTON
- **STATE:** MA
- **ZIP:** 01887
- **BUSINESS PHONE:** 781-222-6000

**MAIL ADDRESS:**
- **STREET 1:** 251 BALLARDVALE ST
- **CITY:** WILMINGTON
- **STATE:** MA
- **ZIP:** 01887

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHARLES RIVER LABORATORIES INTERNATIONAL INC
- **DATE OF NAME CHANGE:** 20000605

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHARLES RIVER LABORATORIES HOLDINGS INC
- **DATE OF NAME CHANGE:** 19991208

?xml version='1.0' encoding='ASCII'? crl-20260218

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**February 18, 2026** 

Date of Report (Date of earliest event reported)

**CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** 

(Exact Name of Registrant as Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-15943** | **06-1397316** |
| (State or Other<br>Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |

---

**251 Ballardvale Street** 

**Wilmington, Massachusetts 01887** 

(Address of Principal Executive Offices) (Zip Code)

**781-222-6000** 

(Registrant's Telephone Number, including Area Code)

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common stock, $0.01 par value | CRL | New York Stock Exchange |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**ITEM 2.02. Results of Operations and Financial Condition** 

The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

On February 18, 2026, Charles River Laboratories International, Inc. issued a press release providing financial results for the fourth quarter and fiscal year ended December 27, 2025.

The press release, attached as an exhibit to this report, includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the press release are "forward-looking" rather than historic. The press release also states that these and other risks relating to Charles River are set forth in the documents filed by Charles River with the Securities and Exchange Commission.

**ITEM 9.01. Financial Statements and Exhibits**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| <u>[99.1](crl4q25earningsrelease.htm)</u> | <u>[Press release dated February 18, 2026](crl4q25earningsrelease.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** |
| Date: | February 18, 2026 | By: | /s/ Matthew L. Daniel |
|  |  |  | Matthew L. Daniel, Corporate Senior Vice President, |
|  |  |  | General Counsel, Corporate Secretary & Chief Compliance Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![image_0a.jpg](image_0a.jpg)

**NEWS RELEASE**

**CHARLES RIVER LABORATORIES ANNOUNCES FOURTH-QUARTER** 

**AND FULL-YEAR 2025 RESULTS AND PROVIDES 2026 GUIDANCE**

**– Fourth-Quarter Revenue of $994.2 Million** 

**and Full-Year Revenue of $4.02 Billion –**

**– Fourth-Quarter GAAP Loss per Share of $(5.62)<br>and Non-GAAP Earnings per Share of $2.39 –**

**– Full-Year GAAP Loss per Share of $(2.91)<br>and Non-GAAP Earnings per Share of $10.28 –**

**– Provides 2026 Guidance –**

**WILMINGTON, MA, February 18, 2026** – Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth quarter and full-year 2025 and provided guidance for 2026. For the quarter, revenue was $994.2 million, a decrease of 0.8% from $1,002.5 million in the fourth quarter of 2024.

The impact of foreign currency translation increased reported revenue by 1.9%, and the divestiture of a small Safety Assessment site in 2024 reduced reported revenue by 0.1%. Excluding the effect of these items, revenue declined 2.6% on an organic basis, driven primarily by the Discovery and Safety Assessment (DSA) and Manufacturing Solutions (Manufacturing) segments.

In the fourth quarter of 2025, the GAAP operating margin was (28.5)%, compared to (16.7)% in the fourth quarter of 2024. The GAAP net loss available to common shareholders for the fourth quarter of 2025 was $(276.6) million, or $(5.62) per diluted share, compared to a net loss of $(215.7) million, or $(4.22) per diluted share for the same period in 2024. GAAP net income and earnings per share included non-cash intangible asset impairments of $211.0 million, or $3.22 per share, for the Biologics Solutions reporting unit (Manufacturing segment) and the Cell Solutions business (RMS segment) and a non-cash goodwill impairment totaling $165.0 million, or $3.35 per share, in the Biologics Solutions reporting unit in the fourth quarter of 2025, compared to a non-cash goodwill impairment of $215.0 million, or $4.20 per share, in the Biologics Solutions reporting unit in the fourth quarter of 2024. In the fourth quarter of 2025, the Company reported a gain of $0.10 per share on certain venture capital and other strategic investments, compared to a loss of $0.32 per share in the fourth quarter of 2024.

------

On a non-GAAP basis, the fourth-quarter operating margin decreased to 18.1% from 19.9% in the fourth quarter of 2024, primarily as a result of lower revenue, higher study-related direct costs in the DSA segment, and an unfavorable revenue mix in the RMS segment. Non-GAAP net income was $118.8 million for the fourth quarter of 2025, a decrease of 13.0% from $136.6 million for the same period in 2024. Fourth-quarter diluted earnings per share on a non-GAAP basis were $2.39, a decrease of 10.2% from $2.66 per share for the fourth quarter of 2024. The non-GAAP net income and earnings per share decreases were driven primarily by lower revenue and operating margin, as well as a higher tax rate.

James C. Foster, Chair, President and Chief Executive Officer, said, "We were pleased with our 2025 financial results, including substantial improvement in DSA net bookings in the fourth quarter that demonstrates the stabilization of the biopharmaceutical demand environment. We are making significant progress on several strategic initiatives that will enable the Company to better capitalize on future growth opportunities, and we remain intently focused on scientific innovation that will reinforce our position as the leader in preclinical drug development."

"As we look ahead, we are cautiously optimistic that positive demand trends will continue in 2026. We remain committed to driving our strategy forward, including through selective and strategic acquisitions that align with our core competencies; taking decisive actions to drive efficiency and process improvements that will deliver continued benefits; and by strengthening and refining our organization to enhance our speed and responsiveness. This approach ensures Charles River remains the partner of choice for our clients as the biopharmaceutical demand environment continues to improve," Mr. Foster concluded.

**<u>Fourth-Quarter Segment Results</u>**

***Research Models and Services (RMS)***

Revenue for the RMS segment was $206.3 million in the fourth quarter of 2025, an increase of 1.0% from $204.3 million in the fourth quarter of 2024. The impact of foreign currency translation increased revenue by 1.9%. Organic revenue decreased by 0.9%, due primarily to lower revenue for large research models and for small research models in North America. The decline was partially offset by higher revenue for research model services, including in the Insourcing Solutions business, and small research models in China and Europe.

In the fourth quarter of 2025, the RMS segment's GAAP operating margin decreased to (33.6)% from 6.7% in the fourth quarter of 2024 primarily due to the intangible asset impairment related to the Cell Solutions business. On a non-GAAP basis, the operating margin decreased to 21.9% from 22.8%. The non-GAAP operating margin decrease was primarily driven by the unfavorable revenue mix related to large research models and lower revenue for small research models in North America.

***Discovery and Safety Assessment (DSA)***

Revenue for the DSA segment was $591.6 million in the fourth quarter of 2025, a decrease of 2.0% from $603.3 million in the fourth quarter of 2024. The impact of foreign currency translation increased DSA revenue by 1.5% and the divestiture of a small DSA site reduced

------

reported revenue by 0.2%. Organic revenue decreased by 3.3%, driven primarily by lower sales volume for discovery services, and also for regulated safety assessment services.

In the fourth quarter of 2025, the DSA segment's GAAP operating margin increased to 14.3% from 10.4% in the fourth quarter of 2024. The increase was primarily driven by a favorable comparison to the prior year's large model (NHP) inventory write down. On a non-GAAP basis, the operating margin decreased to 20.1% from 24.7% in the fourth quarter of 2024. The non-GAAP operating margin decrease was primarily driven by lower revenue, as well as higher study-related direct costs related to large-model sourcing and staffing.

***Manufacturing Solutions (Manufacturing)***

Revenue for the Manufacturing segment was $196.4 million in the fourth quarter of 2025, an increase of 0.7% from $194.9 million in the fourth quarter of 2024. The impact of foreign currency translation increased Manufacturing revenue by 2.8%. Organic revenue decreased 2.1%, driven by lower revenue in the CDMO business, partially offset by higher revenue in the Microbial Solutions and Biologics Testing businesses.

The Manufacturing segment's GAAP operating margin was (115.9)%, compared to (93.6)% in the fourth quarter of 2024. The decrease was primarily the result of larger impairments in the fourth quarter of 2025 related to the Biologics Solutions reporting unit, which includes both the CDMO and Biologics Testing businesses. On a non-GAAP basis, the operating margin increased to 32.1% from 28.7% in the fourth quarter of 2024, driven primarily by the benefit of cost savings resulting from the Company's restructuring initiatives.

**<u>Full-Year Results</u>**

For 2025, revenue decreased by 0.9% to $4.02 billion from $4.05 billion in 2024. Revenue declined by 1.6% on an organic basis.

The GAAP operating margin decreased to 0.6% from 5.6% in 2024, and on a non-GAAP basis, the operating margin decreased to 19.8% from 19.9%.

On a GAAP basis, the net loss available to common shareholders was $(144.3) million in 2025, a decrease from net income available to common shareholders of $10.3 million in 2024. The diluted loss per share on a GAAP basis in 2025 was $(2.91), a decrease from diluted earnings per share of $0.20 in 2024.

On a non-GAAP basis, net income was $512.3 million in 2025, a decrease of 3.9% from $532.9 million in 2024. Diluted earnings per share on a non-GAAP basis in 2025 were $10.28, a decrease of 0.4% from $10.32 in 2024.

***Research Models and Services (RMS)***

For 2025, RMS revenue was $846.1 million, an increase of 2.0% from $829.4 million in 2024. Revenue increased by 1.2% on an organic basis.

------

On a GAAP basis, the RMS segment operating margin decreased to 5.3% in 2025 from 13.8% in 2024. On a non-GAAP basis, the operating margin increased to 24.8% in 2025 from 23.7% in 2024.

***Discovery and Safety Assessment (DSA)***

For 2025, DSA revenue was $2.40 billion, a decrease of 2.0% from $2.45 billion in 2024. Revenue declined by 2.6% on an organic basis.

On a GAAP basis, the DSA segment operating margin decreased to 17.7% in 2025 from 18.1% in 2024. On a non-GAAP basis, the operating margin decreased to 24.2% in 2025 from 25.7% in 2024.

***Manufacturing Solutions (Manufacturing)***

For 2025, Manufacturing revenue was $766.4 million, a decrease of 0.4% from $769.3 million in 2024. Revenue declined by 1.6% on an organic basis.

On a GAAP basis, the Manufacturing segment operating margin decreased to (24.0)% in 2025 from (9.3)% in 2024. On a non-GAAP basis, the operating margin increased to 28.8% in 2025 from 27.4% in 2024.

**<u>2026 Guidance</u>**

The Company is providing financial guidance for 2026, which does not include the impact of planned divestitures that represent approximately 7% of annual revenue for 2025 and estimated 2026. On an organic basis, this outlook assumes that the robust DSA booking trends in the fourth quarter of 2025, combined with an expectation that favorable booking activity will continue in 2026, will result in a return to organic revenue growth in the second half of 2026 on both a consolidated basis and for the DSA segment. In addition, the Company also expects revenue will increase organically in the Manufacturing segment, as a result of the anniversary of the loss of a large, commercial CDMO client in 2025 and a continuation of solid demand trends in the Microbial Solutions business. The revenue increase is expected to be partially offset by lower revenue in the RMS segment due to lower large model revenue, as well as lower revenue in its Insourcing Solutions business, principally related to its CRADL<sup>TM</sup> operations.

Non-GAAP earnings per share are expected to increase by approximately 4% to 9% in 2026, as a result of the benefit from incremental cost savings related to restructuring and efficiency initiatives, as well as the earnings accretion from the completed acquisition of the assets of K.F. (Cambodia) Ltd. A lower tax rate will also contribute to non-GAAP earnings per share growth in 2026.

The Company's 2026 guidance for revenue and earnings per share is as follows:

------

---

| | |
|:---|:---|
| **2026 GUIDANCE (1)** | |
| Revenue growth/(decrease), reported | At Least Flat to +1.5% |
| Impact of divestitures/(acquisitions), net | 0.0% - (0.5)% |
| (Favorable)/unfavorable impact of foreign exchange | (1.0)% - (1.5)% |
| Revenue growth/(decrease), organic (2) | (1.0)% to At Least Flat |
| GAAP EPS estimate | $6.30 – $6.80 |
| Acquisition-related amortization and other acquisition- and integration-related costs (3) | $3.50 – $3.60 |
| Costs associated with restructuring actions (4) | $0.80 – $0.85 |
| Non-GAAP EPS estimate | $10.70 – $11.20 |

---

<u>Footnotes to Guidance Table:</u>

(1) Revenue and earnings per share of the planned divested businesses remain embedded in the Company's guidance for the full-year 2026.

(2) Organic revenue growth is defined as reported revenue growth adjusted for completed acquisitions and divestitures (as well as the planned acquisition of PathoQuest SAS), as well as foreign currency translation.

(3) These adjustments primarily include amortization related to intangible assets, as well as the purchase accounting step-up on inventory and certain long-term biological assets. In addition, these adjustments include some costs related to the evaluation and integration of acquisitions and divestitures.

(4) These adjustments primarily include site consolidation (including site transition costs), severance, impairment, and other costs related to the Company's restructuring actions.

**<u>Webcast</u>**

Charles River has scheduled a live webcast on Wednesday, February 18<sup>th</sup>, at 8:30 a.m. ET to discuss matters relating to this press release. To participate, please go to <u>ir.criver.com</u> and select the webcast link. You can also find the associated slide presentation and reconciliations of GAAP financial measures to non-GAAP financial measures on the website.

**<u>Non-GAAP Reconciliations</u>**

The Company reports non-GAAP results in this press release, which exclude often-one-time charges and other items that are outside of normal operations. A reconciliation of GAAP to non-GAAP results is provided in the schedules at the end of this press release.

**<u>Use of Non-GAAP Financial Measures</u>**

This press release contains non-GAAP financial measures, such as non-GAAP earnings per share, non-GAAP operating income, non-GAAP operating margin, and non-GAAP net income. Non-GAAP financial measures exclude, but are not limited to, the amortization of intangible assets and the purchase accounting step-up adjustment on inventory and certain long term biological assets, and other charges and adjustments related to our acquisitions and divestitures, including expenses associated with evaluating and integrating acquisitions and divestitures, including advisory fees, certain transition costs, and certain other transaction-related costs, as well as fair value adjustments associated with contingent consideration; charges, gains, and

------

losses attributable to businesses or properties we plan to close, consolidate, or divest; severance and other costs associated with our restructuring initiatives; the write-off of deferred financing costs and fees related to debt financing; investment gains or losses associated with our venture capital and certain other strategic equity investments; certain legal costs in our DSA segment related to now concluded U.S. government investigations into the NHP supply chain and advisory costs related to entering into a Cooperation Agreement with a shareholder; tax effect of all of the aforementioned matters; and adjustments related to the derecognition of certain deferred tax assets due to the CDMO Gene Therapy intangible asset impairment charge, the recognition of deferred tax assets expected to be utilized as a result of changes to the Company's international financing structure, and the revaluation of deferred tax liabilities as a result of foreign tax legislation. This press release also refers to our revenue on both a GAAP and non-GAAP basis: on a non-GAAP basis, we define "organic revenue growth" as reported revenue growth adjusted for foreign currency translation, acquisitions, and divestitures. We exclude these items from the non-GAAP financial measures because they are outside our normal operations. There are limitations in using non-GAAP financial measures, as they are not presented in accordance with generally accepted accounting principles, and may be different than non-GAAP financial measures used by other companies. In particular, we believe that the inclusion of supplementary non-GAAP financial measures in this press release helps investors to gain a meaningful understanding of our core operating results and future prospects without the effect of these often-one-time charges, and is consistent with how management measures and forecasts the Company's performance, especially when comparing such results to prior periods or forecasts. We believe that the financial impact of our acquisitions and divestitures (and in certain cases, the evaluation of such acquisitions and divestitures, whether or not ultimately consummated) is often large relative to our overall financial performance, which can adversely affect the comparability of our results on a period-to-period basis. In addition, certain activities and their underlying associated costs, such as business acquisitions, generally occur periodically but on an unpredictable basis. We calculate non-GAAP integration costs to include third-party integration costs incurred post-acquisition. Presenting revenue on an organic basis allows investors to measure our revenue growth exclusive of acquisitions, divestitures, and foreign currency exchange fluctuations more clearly. Non-GAAP results also allow investors to compare the Company's operations against the financial results of other companies in the industry who similarly provide non-GAAP results. The non-GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations presented in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. Reconciliations of the non-GAAP financial measures used in this press release to the most directly comparable GAAP financial measures are set forth in this press release, and can also be found on the Company's website at ir.criver.com.

**<u>Caution Concerning Forward-Looking Statements</u>**

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "intend," "will," "would," "may," "estimate," "plan," "outlook," and "project," and other similar expressions that predict or

------

indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding: the projected future financial performance of Charles River and our specific businesses, including as delineated in our forward-looking guidance, and particularly our expectations with respect to revenue, the impact of foreign exchange, interest rates, and enhanced efficiency initiatives; our expectations with respect to the impact of NHP supply constraints and our ability to gain market share; our ability to create long-term value for our shareholders and successfully execute on our strategic initiatives, including the impact and results of the such initiatives; the Company's plans or prospects, expectations and long-term goals associated with our business; earnings per share; operating margin; client demand, particularly the future demand for drug discovery and development products and services, including our expectations for future revenue trends; our expectations with respect to booking trends and the impacts thereof; our expectations with respect to pricing of our products and services; our expectations with respect to future tax rates and the impact of such tax rates on our business; our expectations with respect to the impact of acquisitions, including the acquisition of the assets of K.F. (Cambodia) Ltd. and the planned acquisition of PathoQuest SAS, and divestitures on the Company, our service offerings, client perception, strategic relationships, revenue, revenue growth rates, revenue growth drivers, and earnings; the development and performance of our services and products, including our investments in our portfolio; market and industry conditions including the outsourcing of services and identification of spending trends by our clients and funding available to them; ability to gain market share and capitalize on business and growth opportunities; the impact of our restructuring initiatives, including annualized savings; and the impact of our stock repurchase authorization. Forward-looking statements are based on Charles River's current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: the impact of NHP supply constraints; changes and uncertainties in the global economy and financial markets, including disruptions in the global economy caused by geopolitical conflicts; the ability to successfully integrate businesses we acquire, and risks and uncertainties associated with businesses that we acquire; the ability to successfully complete the planned acquisition of PathoQuest SAS; the timing and magnitude of our share repurchases; negative trends in research and development spending, negative trends in the level of outsourced services, or other cost reduction actions by our clients; the ability to convert backlog to revenue; demand and booking trends; special interest groups; contaminations; industry trends; new displacement technologies; USDA and FDA regulations; changes in law; continued availability of products and supplies; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in tax regulation and laws; changes in generally accepted accounting principles; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 18, 2026, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this press release except as required by law.

------

**About Charles River**

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

\# \# \#

Investor Contact:&nbsp;&nbsp;&nbsp;&nbsp;Media Contact:

Todd Spencer&nbsp;&nbsp;&nbsp;&nbsp;Amy Cianciaruso

Corporate Vice President,&nbsp;&nbsp;&nbsp;&nbsp;Corporate Senior Vice President,

Investor Relations&nbsp;&nbsp;&nbsp;&nbsp;Chief Communications Officer

781.222.6455&nbsp;&nbsp;&nbsp;&nbsp;781.222.6168

<u>todd.spencer@crl.com</u>&nbsp;&nbsp;&nbsp;&nbsp;<u>amy.cianciaruso@crl.com</u>

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** |
| **SCHEDULE 1** | **SCHEDULE 1** | **SCHEDULE 1** | **SCHEDULE 1** | **SCHEDULE 1** |
| **CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)** | **CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)** | **CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)** | **CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)** | **CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)** |
| **(in thousands, except for per share data)** | **(in thousands, except for per share data)** | **(in thousands, except for per share data)** | **(in thousands, except for per share data)** | **(in thousands, except for per share data)** |
| | **Three Months Ended** | **Three Months Ended** | **Twelve Months Ended** | **Twelve Months Ended** |
| | **December 27, 2025** | **December 28, 2024** | **December 27, 2025** | **December 28, 2024** |
| Service revenue | $803298 | $811913 | $3250099 | $3304138 |
| Product revenue | 190929 | 190636 | 765283 | 745851 |
| &nbsp;&nbsp;&nbsp;Total revenue | 994227 | 1002549 | 4015382 | 4049989 |
| Costs and expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Cost of services provided (excluding amortization of intangible assets) | 579821 | 621535 | 2314760 | 2345781 |
| &nbsp;&nbsp;&nbsp;Cost of products sold (excluding amortization of intangible assets) | 104722 | 96770 | 377347 | 372387 |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 196136 | 195708 | 743073 | 751003 |
| &nbsp;&nbsp;&nbsp;Amortization of intangible assets | 21014 | 41223 | 179066 | 138471 |
| &nbsp;&nbsp;Intangible asset impairment | 210974 |  | 210974 |  |
| &nbsp;&nbsp;Goodwill impairment | 165000 | 215000 | 165000 | 215000 |
| Operating income (loss) | (283440) | (167687) | 25162 | 227347 |
| Other income (expense): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest income | 1017 | 1835 | 4940 | 8575 |
| &nbsp;&nbsp;&nbsp;Interest expense | (23775) | (28234) | (107029) | (126288) |
| &nbsp;&nbsp;&nbsp;Other income (expense), net | 12099 | (22705) | (22576) | (16520) |
| Income (loss) before income taxes | (294099) | (216791) | (99503) | 93114 |
| Provision for income taxes | (17809) | (3044) | 42660 | 67823 |
| Net income (loss) | (276290) | (213747) | (142163) | 25291 |
| &nbsp;&nbsp;&nbsp;Less: Net income attributable to noncontrolling interests | 265 | 748 | 2175 | 3088 |
| Net income (loss) attributable to Charles River Laboratories International, Inc. | $(276555) | $(214495) | $(144338) | $22203 |
| Calculation of net income (loss) per share attributable to Charles River Laboratories International, Inc. common shareholders |  |  |  |  |
| Net income (loss) attributable to Charles River Laboratories International, Inc. | $(276555) | $(214495) | $(144338) | $22203 |
| &nbsp;&nbsp;Less: Adjustment of redeemable noncontrolling interest |  | (1081) |  |  |
| &nbsp;&nbsp;Less: Incremental dividends attributed to noncontrolling interest holders |  | 2285 |  | 11906 |
| Net income (loss) available to Charles River Laboratories International, Inc. common shareholders | $(276555) | $(215699) | $(144338) | $10297 |
| Earnings (loss) per common share |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $(5.62) | $(4.22) | $(2.91) | $0.20 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $(5.62) | $(4.22) | $(2.91) | $0.20 |
| Weighted-average number of common shares outstanding |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic | 49216 | 51138 | 49564 | 51380 |
| &nbsp;&nbsp;&nbsp;Diluted | 49216 | 51138 | 49564 | 51628 |

---

------

---

| | | |
|:---|:---|:---|
| **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** |
| **SCHEDULE 2** | **SCHEDULE 2** | **SCHEDULE 2** |
| **CONDENSED CONSOLIDATED BALANCE SHEETS** | **CONDENSED CONSOLIDATED BALANCE SHEETS** | **CONDENSED CONSOLIDATED BALANCE SHEETS** |
| **(in thousands, except per share amounts)** | **(in thousands, except per share amounts)** | **(in thousands, except per share amounts)** |
| | **December 27, 2025** | **December 28, 2024** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $213770 | $194606 |
| &nbsp;&nbsp;Trade receivables and contract assets, net of allowances for credit losses of $10,463 and $18,301, respectively | 708856 | 720915 |
| &nbsp;&nbsp;&nbsp;Inventories | 299103 | 278544 |
| &nbsp;&nbsp;&nbsp;Prepaid assets | 96108 | 103210 |
| &nbsp;&nbsp;&nbsp;Other current assets | 129212 | 105796 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 1447049 | 1403071 |
| Property, plant and equipment, net | 1655219 | 1604014 |
| Venture capital and strategic equity investments | 206972 | 218350 |
| Operating lease right-of-use assets, net | 361415 | 412490 |
| Goodwill | 2764253 | 2846608 |
| Intangible assets, net | 339995 | 723400 |
| Deferred tax assets | 67334 | 42179 |
| Other assets | 293185 | 278233 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $7135422 | $7528345 |
| **Liabilities, Redeemable Noncontrolling Interests and Equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $148800 | $140337 |
| &nbsp;&nbsp;&nbsp;Accrued compensation | 268854 | 179418 |
| &nbsp;&nbsp;&nbsp;Deferred revenue | 210418 | 248322 |
| &nbsp;&nbsp;&nbsp;Accrued liabilities | 270085 | 232010 |
| &nbsp;&nbsp;&nbsp;Other current liabilities | 222158 | 194014 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 1120315 | 994101 |
| Long-term debt, net and finance leases | 2136360 | 2240205 |
| Operating lease right-of-use liabilities | 434048 | 483789 |
| Deferred tax liabilities | 95203 | 106960 |
| Other long-term liabilities | 138302 | 195212 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 3924228 | 4020267 |
| Redeemable noncontrolling interests | 41263 | 41126 |
| Equity: |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding |  |  |
| &nbsp;&nbsp;Common stock, $0.01 par value; 120,000 shares authorized; 49,217 shares issued and outstanding as of December 27, 2025 and 51,141 shares issued and outstanding as of December 28, 2024 | 492 | 511 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 1947301 | 1966237 |
| &nbsp;&nbsp;&nbsp;Retained earnings | 1388620 | 1812100 |
| &nbsp;&nbsp;Treasury stock, at cost, zero shares as of December 27, 2025 and December 28, 2024 |  |  |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (171783) | (317345) |
| Total Charles River Laboratories International, Inc. equity | 3164630 | 3461503 |
| Nonredeemable noncontrolling interest | 5301 | 5449 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total equity | 3169931 | 3466952 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities, redeemable noncontrolling interests and equity | $7135422 | $7528345 |

---

------

---

| | | |
|:---|:---|:---|
| **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** |
| **SCHEDULE 3** | **SCHEDULE 3** | **SCHEDULE 3** |
| **CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS** | **CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS** | **CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS** |
| **(in thousands)** | **(in thousands)** | **(in thousands)** |
| | **Twelve Months Ended** | **Twelve Months Ended** |
| | **December 27, 2025** | **December 28, 2024** |
| **Cash flows relating to operating activities** | | |
| Net income (loss) | $(142163) | $25291 |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net income (loss) to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 403312 | 361741 |
| &nbsp;&nbsp;&nbsp;Goodwill impairment | 165000 | 215000 |
| &nbsp;&nbsp;&nbsp;Long-lived asset impairments | 259080 | 51825 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation | 71083 | 69891 |
| &nbsp;&nbsp;&nbsp;Deferred income taxes | (75292) | (67428) |
| &nbsp;&nbsp;&nbsp;Write down of inventories | 12444 | 46992 |
| &nbsp;&nbsp;&nbsp;(Gains) losses and impairments on venture capital and strategic equity investments, net | 24911 | 12910 |
| &nbsp;&nbsp;&nbsp;Provision for credit losses | 6062 | 14774 |
| &nbsp;&nbsp;&nbsp;(Gain) loss on divestitures, net | (3376) | 659 |
| &nbsp;&nbsp;&nbsp;Other, net | 2504 | 33251 |
| Changes in assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Trade receivables and contract assets, net | 35737 | 21612 |
| &nbsp;&nbsp;&nbsp;Inventories | (48777) | 16804 |
| &nbsp;&nbsp;&nbsp;Accounts payable | 2869 | (14271) |
| &nbsp;&nbsp;&nbsp;Accrued compensation | 79308 | (27604) |
| &nbsp;&nbsp;&nbsp;Deferred revenue | (38139) | 18541 |
| &nbsp;&nbsp;&nbsp;Customer contract deposits | 14652 | 6584 |
| &nbsp;&nbsp;&nbsp;Other assets and liabilities, net | (31569) | (51995) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 737646 | 734577 |
| **Cash flows relating to investing activities** |  |  |
| &nbsp;&nbsp;&nbsp;Capital expenditures | (219152) | (232967) |
| &nbsp;&nbsp;&nbsp;Purchases of investments and contributions to venture capital investments | (20076) | (52876) |
| &nbsp;&nbsp;&nbsp;Acquisition of businesses and assets, net of cash acquired |  | (5479) |
| &nbsp;&nbsp;&nbsp;Proceeds from sale of investments | 9102 | 41687 |
| &nbsp;&nbsp;&nbsp;Proceeds from sale of businesses, net | 17441 |  |
| &nbsp;&nbsp;&nbsp;Other, net | 3364 | 4549 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (209321) | (245086) |
| **Cash flows relating to financing activities** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from long-term debt and revolving credit facility | 1227534 | 1081581 |
| &nbsp;&nbsp;&nbsp;Payments on long-term debt, revolving credit facility, and finance lease obligations | (1349317) | (1493769) |
| &nbsp;&nbsp;&nbsp;Proceeds from exercises of stock options | 714 | 23878 |
| &nbsp;&nbsp;&nbsp;Purchase of treasury stock | (360673) | (119175) |
| &nbsp;&nbsp;&nbsp;Payments of contingent consideration | (21822) |  |
| &nbsp;&nbsp;&nbsp;Purchase of remaining equity interests of other redeemable noncontrolling interest | (19140) | (12000) |
| &nbsp;&nbsp;&nbsp;Other, net | (14022) | (31442) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities | (536726) | (550927) |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 18828 | (17474) |
| Net change in cash, cash equivalents, and restricted cash | 10427 | (78910) |
| Cash, cash equivalents, and restricted cash, beginning of period | 205570 | 284480 |
| **Cash, cash equivalents, and restricted cash, end of period** | $215997 | $205570 |

---

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** |
| **SCHEDULE 4** | **SCHEDULE 4** | **SCHEDULE 4** | **SCHEDULE 4** | **SCHEDULE 4** | **SCHEDULE 4** |
| **RECONCILIATION OF GAAP TO NON-GAAP** | **RECONCILIATION OF GAAP TO NON-GAAP** | **RECONCILIATION OF GAAP TO NON-GAAP** | **RECONCILIATION OF GAAP TO NON-GAAP** | **RECONCILIATION OF GAAP TO NON-GAAP** | **RECONCILIATION OF GAAP TO NON-GAAP** |
| **SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)**<sup>(1)</sup> | **SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)**<sup>(1)</sup> | **SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)**<sup>(1)</sup> | **SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)**<sup>(1)</sup> | **SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)**<sup>(1)</sup> | **SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)**<sup>(1)</sup> |
| **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** |
| | | **Three Months Ended** | **Three Months Ended** | **Twelve Months Ended** | **Twelve Months Ended** |
| | | **December 27, 2025** | **December 28, 2024** | **December 27, 2025** | **December 28, 2024** |
| **Research Models and Services** | **Research Models and Services** | | | | |
|  | Revenue | $206264 | $204257 | $846082 | $829377 |
|  | Operating income (loss) | (69377) | 13770 | 44567 | 114411 |
|  | Operating income (loss) as a % of revenue | (33.6)% | 6.7% | 5.3% | 13.8% |
|  | Add back: |  |  |  |  |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Amortization related to acquisitions | 8565 | 11327 | 44831 | 38058 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Acquisition, integration, and divestiture-related adjustments <sup>(3)</sup> | (14) | 93 |  | 430 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Severance | 942 | 1220 | 4606 | 4905 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Intangible asset impairment <sup>(4)</sup> | 102000 |  | 102000 |  |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Asset impairment | 501 | 18317 | 7959 | 33226 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Site consolidation charges | 2601 | 1812 | 6146 | 5795 |
|  | Total non-GAAP adjustments to operating income | $114595 | $32769 | $165542 | $82414 |
|  | Operating income, excluding non-GAAP adjustments | $45218 | $46539 | $210109 | $196825 |
|  | Non-GAAP operating income as a % of revenue | 21.9% | 22.8% | 24.8% | 23.7% |
|  | Depreciation and amortization | $17665 | $20762 | $81075 | $73812 |
|  | Capital expenditures | $24739 | $27591 | $38838 | $64134 |
| **Discovery and Safety Assessment** | **Discovery and Safety Assessment** |  |  |  |  |
|  | Revenue | $591568 | $603349 | $2402891 | $2451280 |
|  | Operating income | 84669 | 62859 | 424555 | 442510 |
|  | Operating income as a % of revenue | 14.3% | 10.4% | 17.7% | 18.1% |
|  | Add back: |  |  |  |  |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Amortization related to acquisitions | 20547 | 22301 | 76128 | 81013 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Acquisition, integration, and divestiture-related adjustments <sup>(3)</sup> | 3995 | 9636 | 8750 | 17133 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Severance | 6744 | 8095 | 11812 | 28558 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Asset impairment | 2915 | 5360 | 25305 | 6424 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Site consolidation charges | 3873 | 2094 | 14563 | 4698 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Third-party legal and advisory costs and certain related items <sup>(6)</sup> | (3880) | 38634 | 21149 | 49648 |
|  | Total non-GAAP adjustments to operating income | $34194 | $86120 | $157707 | $187474 |
|  | Operating income, excluding non-GAAP adjustments | $118863 | $148979 | $582262 | $629984 |
|  | Non-GAAP operating income as a % of revenue | 20.1% | 24.7% | 24.2% | 25.7% |
|  | Depreciation and amortization | $45370 | $49857 | $174030 | $191126 |
|  | Capital expenditures | $54229 | $37180 | $132959 | $128356 |
| **Manufacturing Solutions** | **Manufacturing Solutions** |  |  |  |  |
|  | Revenue | $196395 | $194943 | $766409 | $769332 |
|  | Operating loss | (227651) | (182552) | (184284) | (71453) |
|  | Operating loss as a % of revenue | (115.9)% | (93.6)% | (24.0)% | (9.3)% |
|  | Add back: |  |  |  |  |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Amortization related to acquisitions <sup>(2)</sup> | 4103 | 20108 | 104778 | 52471 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Acquisition, integration, and divestiture-related adjustments <sup>(3)</sup> |  | 53 |  | 1439 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Severance | 2151 | 3091 | 5253 | 11177 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Intangible asset impairment <sup>(4)</sup> | 108974 |  | 108974 |  |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Goodwill impairment <sup>(5)</sup> | 165000 | 215000 | 165000 | 215000 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Asset impairment | 8217 |  | 14666 | 25 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Site consolidation charges | 2276 | 206 | 6515 | 1773 |
|  | Total non-GAAP adjustments to operating income | $290721 | $238458 | $405186 | $281885 |
|  | Operating income, excluding non-GAAP adjustments | $63070 | $55906 | $220902 | $210432 |
|  | Non-GAAP operating income as a % of revenue | 32.1% | 28.7% | 28.8% | 27.4% |
|  | Depreciation and amortization | $12875 | $29788 | $140218 | $89964 |
|  | Capital expenditures | $7796 | $10320 | $41427 | $38500 |
| **Unallocated Corporate Overhead** | **Unallocated Corporate Overhead** | $(71081) | $(61764) | $(259676) | $(258121) |
|  | Add back: |  |  |  |  |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Acquisition, integration, and divestiture-related adjustments <sup>(3)</sup> | 19260 | 8120 | 22923 | 15839 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Severance | 2236 | 309 | 7339 | 9546 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Asset impairment |  | 1239 | 184 | 1239 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Site consolidation charges | 2208 | 200 | 3644 | 200 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Third-party legal and advisory costs <sup>(7)</sup> | 8 |  | 6238 |  |
|  | Total non-GAAP adjustments to operating expense | $23712 | $9868 | $40328 | $26824 |
|  | Unallocated corporate overhead, excluding non-GAAP adjustments | $(47369) | $(51896) | $(219348) | $(231297) |
| **Total** | **Total** |  |  |  |  |
|  | Revenue | $994227 | $1002549 | $4015382 | $4049989 |
|  | Operating income (loss) | (283440) | (167687) | 25162 | 227347 |
|  | Operating income (loss) as a % of revenue | (28.5)% | (16.7)% | 0.6% | 5.6% |
|  | Add back: |  |  |  |  |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Amortization related to acquisitions <sup>(2)</sup> | 33215 | 53736 | 225737 | 171542 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Acquisition, integration, and divestiture-related adjustments <sup>(3)</sup> | 23241 | 17902 | 31673 | 34841 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Severance | 12073 | 12715 | 29010 | 54186 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Intangible asset impairment <sup>(4)</sup> | 210974 |  | 210974 |  |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Goodwill impairment <sup>(5)</sup> | 165000 | 215000 | 165000 | 215000 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Asset impairment | 11633 | 24916 | 48114 | 40914 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Site consolidation charges | 10958 | 4312 | 30868 | 12466 |
|  | &nbsp;&nbsp;&nbsp;&nbsp; Third-party legal and advisory costs and certain related items <sup>(6)</sup> | (3872) | 38634 | 27387 | 49648 |
|  | Total non-GAAP adjustments to operating income | $463222 | $367215 | $768763 | $578597 |
|  | Operating income, excluding non-GAAP adjustments | $179782 | $199528 | $793925 | $805944 |
|  | Non-GAAP operating income as a % of revenue | 18.1% | 19.9% | 19.8% | 19.9% |
|  | Depreciation and amortization | $78277 | $102104 | $403312 | $361741 |
|  | Capital expenditures | $88950 | $75616 | $219152 | $232967 |
| <sup>(1)</sup> | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. |
| <sup>(2)</sup> | Amortization related to acquisitions for the twelve months ended December 27, 2025 and December 28, 2024 includes $71.0 million and $9.4 million, respectively, of accelerated amortization of certain client relationships in the Biologics Solutions reporting unit within the Manufacturing Solutions segment. | Amortization related to acquisitions for the twelve months ended December 27, 2025 and December 28, 2024 includes $71.0 million and $9.4 million, respectively, of accelerated amortization of certain client relationships in the Biologics Solutions reporting unit within the Manufacturing Solutions segment. | Amortization related to acquisitions for the twelve months ended December 27, 2025 and December 28, 2024 includes $71.0 million and $9.4 million, respectively, of accelerated amortization of certain client relationships in the Biologics Solutions reporting unit within the Manufacturing Solutions segment. | Amortization related to acquisitions for the twelve months ended December 27, 2025 and December 28, 2024 includes $71.0 million and $9.4 million, respectively, of accelerated amortization of certain client relationships in the Biologics Solutions reporting unit within the Manufacturing Solutions segment. | Amortization related to acquisitions for the twelve months ended December 27, 2025 and December 28, 2024 includes $71.0 million and $9.4 million, respectively, of accelerated amortization of certain client relationships in the Biologics Solutions reporting unit within the Manufacturing Solutions segment. |
| <sup>(3)</sup> | These adjustments are related to the evaluation and integration of acquisitions and divestitures, and primarily include transaction, advisory, certain third-party integration, certain compensation costs, and related costs; as well as fair value adjustments associated with contingent consideration arrangements. | These adjustments are related to the evaluation and integration of acquisitions and divestitures, and primarily include transaction, advisory, certain third-party integration, certain compensation costs, and related costs; as well as fair value adjustments associated with contingent consideration arrangements. | These adjustments are related to the evaluation and integration of acquisitions and divestitures, and primarily include transaction, advisory, certain third-party integration, certain compensation costs, and related costs; as well as fair value adjustments associated with contingent consideration arrangements. | These adjustments are related to the evaluation and integration of acquisitions and divestitures, and primarily include transaction, advisory, certain third-party integration, certain compensation costs, and related costs; as well as fair value adjustments associated with contingent consideration arrangements. | These adjustments are related to the evaluation and integration of acquisitions and divestitures, and primarily include transaction, advisory, certain third-party integration, certain compensation costs, and related costs; as well as fair value adjustments associated with contingent consideration arrangements. |
| <sup>(4)</sup> | During the fourth quarter ended December 27, 2025, a triggering event was identified for the Cell Solutions asset group within the RMS reporting segment and the CDMO Gene Therapy asset group within the Manufacturing reporting segment, due to a decline in the operating performance in fiscal year 2025. As a result, the Company recognized an intangible asset impairment charge of $102.0 million and $108.9 million in RMS Cell Solutions and Manufacturing CDMO Gene Therapy, respectively. | During the fourth quarter ended December 27, 2025, a triggering event was identified for the Cell Solutions asset group within the RMS reporting segment and the CDMO Gene Therapy asset group within the Manufacturing reporting segment, due to a decline in the operating performance in fiscal year 2025. As a result, the Company recognized an intangible asset impairment charge of $102.0 million and $108.9 million in RMS Cell Solutions and Manufacturing CDMO Gene Therapy, respectively. | During the fourth quarter ended December 27, 2025, a triggering event was identified for the Cell Solutions asset group within the RMS reporting segment and the CDMO Gene Therapy asset group within the Manufacturing reporting segment, due to a decline in the operating performance in fiscal year 2025. As a result, the Company recognized an intangible asset impairment charge of $102.0 million and $108.9 million in RMS Cell Solutions and Manufacturing CDMO Gene Therapy, respectively. | During the fourth quarter ended December 27, 2025, a triggering event was identified for the Cell Solutions asset group within the RMS reporting segment and the CDMO Gene Therapy asset group within the Manufacturing reporting segment, due to a decline in the operating performance in fiscal year 2025. As a result, the Company recognized an intangible asset impairment charge of $102.0 million and $108.9 million in RMS Cell Solutions and Manufacturing CDMO Gene Therapy, respectively. | During the fourth quarter ended December 27, 2025, a triggering event was identified for the Cell Solutions asset group within the RMS reporting segment and the CDMO Gene Therapy asset group within the Manufacturing reporting segment, due to a decline in the operating performance in fiscal year 2025. As a result, the Company recognized an intangible asset impairment charge of $102.0 million and $108.9 million in RMS Cell Solutions and Manufacturing CDMO Gene Therapy, respectively. |
| <sup>(5)</sup> | In fiscal year 2025, upon completion of the quantitative impairment test, it was determined that the fair value of the Biologics Solutions reporting unit did not exceed its carrying value resulting in a goodwill impairment charge of $165.0 million. In December 2024, a triggering event was identified for the Biologics Solutions reporting unit from a loss of key customers, ultimately resulting in a reduction in Biologics Solutions' long range financial outlook. As a result, the Company recognized a goodwill impairment charge of $215.0 million. | In fiscal year 2025, upon completion of the quantitative impairment test, it was determined that the fair value of the Biologics Solutions reporting unit did not exceed its carrying value resulting in a goodwill impairment charge of $165.0 million. In December 2024, a triggering event was identified for the Biologics Solutions reporting unit from a loss of key customers, ultimately resulting in a reduction in Biologics Solutions' long range financial outlook. As a result, the Company recognized a goodwill impairment charge of $215.0 million. | In fiscal year 2025, upon completion of the quantitative impairment test, it was determined that the fair value of the Biologics Solutions reporting unit did not exceed its carrying value resulting in a goodwill impairment charge of $165.0 million. In December 2024, a triggering event was identified for the Biologics Solutions reporting unit from a loss of key customers, ultimately resulting in a reduction in Biologics Solutions' long range financial outlook. As a result, the Company recognized a goodwill impairment charge of $215.0 million. | In fiscal year 2025, upon completion of the quantitative impairment test, it was determined that the fair value of the Biologics Solutions reporting unit did not exceed its carrying value resulting in a goodwill impairment charge of $165.0 million. In December 2024, a triggering event was identified for the Biologics Solutions reporting unit from a loss of key customers, ultimately resulting in a reduction in Biologics Solutions' long range financial outlook. As a result, the Company recognized a goodwill impairment charge of $215.0 million. | In fiscal year 2025, upon completion of the quantitative impairment test, it was determined that the fair value of the Biologics Solutions reporting unit did not exceed its carrying value resulting in a goodwill impairment charge of $165.0 million. In December 2024, a triggering event was identified for the Biologics Solutions reporting unit from a loss of key customers, ultimately resulting in a reduction in Biologics Solutions' long range financial outlook. As a result, the Company recognized a goodwill impairment charge of $215.0 million. |
| <sup>(6)</sup> | Third-party legal and advisory costs incurred within Unallocated Corporate are associated with the execution of the Cooperation Agreement with a shareholder. Within our DSA business, third-party legal costs incurred are associated with investigations by the U.S. government into the NHP supply chain. In fiscal year 2024, a $27 million inventory charge was incurred within DSA to write down inventory associated with the Cambodia-sourced non-human primate matter from February 16, 2023. Additionally included within DSA, due to the utilization of NHPs, are reductions to the previous $27 million inventory charge, as a result of the resolution of the case during fiscal year 2025. | Third-party legal and advisory costs incurred within Unallocated Corporate are associated with the execution of the Cooperation Agreement with a shareholder. Within our DSA business, third-party legal costs incurred are associated with investigations by the U.S. government into the NHP supply chain. In fiscal year 2024, a $27 million inventory charge was incurred within DSA to write down inventory associated with the Cambodia-sourced non-human primate matter from February 16, 2023. Additionally included within DSA, due to the utilization of NHPs, are reductions to the previous $27 million inventory charge, as a result of the resolution of the case during fiscal year 2025. | Third-party legal and advisory costs incurred within Unallocated Corporate are associated with the execution of the Cooperation Agreement with a shareholder. Within our DSA business, third-party legal costs incurred are associated with investigations by the U.S. government into the NHP supply chain. In fiscal year 2024, a $27 million inventory charge was incurred within DSA to write down inventory associated with the Cambodia-sourced non-human primate matter from February 16, 2023. Additionally included within DSA, due to the utilization of NHPs, are reductions to the previous $27 million inventory charge, as a result of the resolution of the case during fiscal year 2025. | Third-party legal and advisory costs incurred within Unallocated Corporate are associated with the execution of the Cooperation Agreement with a shareholder. Within our DSA business, third-party legal costs incurred are associated with investigations by the U.S. government into the NHP supply chain. In fiscal year 2024, a $27 million inventory charge was incurred within DSA to write down inventory associated with the Cambodia-sourced non-human primate matter from February 16, 2023. Additionally included within DSA, due to the utilization of NHPs, are reductions to the previous $27 million inventory charge, as a result of the resolution of the case during fiscal year 2025. | Third-party legal and advisory costs incurred within Unallocated Corporate are associated with the execution of the Cooperation Agreement with a shareholder. Within our DSA business, third-party legal costs incurred are associated with investigations by the U.S. government into the NHP supply chain. In fiscal year 2024, a $27 million inventory charge was incurred within DSA to write down inventory associated with the Cambodia-sourced non-human primate matter from February 16, 2023. Additionally included within DSA, due to the utilization of NHPs, are reductions to the previous $27 million inventory charge, as a result of the resolution of the case during fiscal year 2025. |

---

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** |
| **SCHEDULE 5** | **SCHEDULE 5** | **SCHEDULE 5** | **SCHEDULE 5** | **SCHEDULE 5** | **SCHEDULE 5** |
| **RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (UNAUDITED)**<sup>(1)</sup> | **RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (UNAUDITED)**<sup>(1)</sup> | **RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (UNAUDITED)**<sup>(1)</sup> | **RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (UNAUDITED)**<sup>(1)</sup> | **RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (UNAUDITED)**<sup>(1)</sup> | **RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (UNAUDITED)**<sup>(1)</sup> |
| **(in thousands, except per share data)** | **(in thousands, except per share data)** | **(in thousands, except per share data)** | **(in thousands, except per share data)** | **(in thousands, except per share data)** | **(in thousands, except per share data)** |
| | | **Three Months Ended** | **Three Months Ended** | **Twelve Months Ended** | **Twelve Months Ended** |
| | | **December 27, 2025** | **December 28, 2024** | **December 27, 2025** | **December 28, 2024** |
| Net income (loss) available to Charles River Laboratories International, Inc. common shareholders | Net income (loss) available to Charles River Laboratories International, Inc. common shareholders | $(276555) | $(215699) | $(144338) | $10297 |
| Add back: | Add back: |  |  |  |  |
| &nbsp;&nbsp;Adjustment of redeemable noncontrolling interest <sup>(2)</sup> | &nbsp;&nbsp;Adjustment of redeemable noncontrolling interest <sup>(2)</sup> |  | (1081) |  |  |
| &nbsp;&nbsp;Incremental dividends attributable to noncontrolling interest holders <sup>(3)</sup> | &nbsp;&nbsp;Incremental dividends attributable to noncontrolling interest holders <sup>(3)</sup> |  | 2285 |  | 11906 |
| &nbsp;&nbsp;Non-GAAP adjustments to operating income <sup>(4)</sup> | &nbsp;&nbsp;Non-GAAP adjustments to operating income <sup>(4)</sup> | 461994 | 365993 | 764098 | 575324 |
| &nbsp;&nbsp;&nbsp;Venture capital and strategic equity investment (gains) losses and impairments, net | &nbsp;&nbsp;&nbsp;Venture capital and strategic equity investment (gains) losses and impairments, net | (9359) | 21690 | 22235 | 12519 |
| &nbsp;&nbsp;&nbsp;&nbsp;(Gain) loss on divestitures <sup>(5)</sup> | &nbsp;&nbsp;&nbsp;&nbsp;(Gain) loss on divestitures <sup>(5)</sup> |  |  | (3376) | 658 |
| Tax effect of non-GAAP adjustments: | Tax effect of non-GAAP adjustments: |  |  |  |  |
| &nbsp;&nbsp;Non-cash tax provision <sup>(6)</sup> | &nbsp;&nbsp;Non-cash tax provision <sup>(6)</sup> | 8156 | 314 | 8156 | 1818 |
| &nbsp;&nbsp;&nbsp;Enacted tax law changes | &nbsp;&nbsp;&nbsp;Enacted tax law changes |  | 230 | 3236 | 3826 |
| &nbsp;&nbsp;&nbsp;Tax effect of the remaining non-GAAP adjustments | &nbsp;&nbsp;&nbsp;Tax effect of the remaining non-GAAP adjustments | (65401) | (37122) | (137731) | (83445) |
| Net income available to Charles River Laboratories International, Inc. common shareholders, excluding non-GAAP adjustments | Net income available to Charles River Laboratories International, Inc. common shareholders, excluding non-GAAP adjustments | $118835 | $136610 | $512280 | $532903 |
| Weighted average shares outstanding - Basic | Weighted average shares outstanding - Basic | 49216 | 51138 | 49564 | 51380 |
| Effect of dilutive securities: | Effect of dilutive securities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Stock options, restricted stock units and performance share units | &nbsp;&nbsp;&nbsp;Stock options, restricted stock units and performance share units | 416 | 219 | 245 | 248 |
| Weighted average shares outstanding - Diluted | Weighted average shares outstanding - Diluted | 49632 | 51357 | 49809 | 51628 |
| Earnings (loss) per share attributable to common shareholders: | Earnings (loss) per share attributable to common shareholders: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic | &nbsp;&nbsp;&nbsp;Basic | $(5.62) | $(4.22) | $(2.91) | $0.20 |
| &nbsp;&nbsp;Diluted <sup>(7)</sup> | &nbsp;&nbsp;Diluted <sup>(7)</sup> | $(5.62) | $(4.22) | $(2.91) | $0.20 |
| &nbsp;&nbsp;&nbsp;Basic, excluding non-GAAP adjustments | &nbsp;&nbsp;&nbsp;Basic, excluding non-GAAP adjustments | $2.41 | $2.67 | $10.34 | $10.37 |
| &nbsp;&nbsp;Diluted, excluding non-GAAP adjustments <sup>(7)</sup> | &nbsp;&nbsp;Diluted, excluding non-GAAP adjustments <sup>(7)</sup> | $2.39 | $2.66 | $10.28 | $10.32 |
| <sup>(1)</sup> | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. |
| <sup>(2)</sup> | This amount represents accretion adjustments of the Noveprim redeemable noncontrolling interest. | This amount represents accretion adjustments of the Noveprim redeemable noncontrolling interest. | This amount represents accretion adjustments of the Noveprim redeemable noncontrolling interest. | This amount represents accretion adjustments of the Noveprim redeemable noncontrolling interest. | This amount represents accretion adjustments of the Noveprim redeemable noncontrolling interest. |
| <sup>(3)</sup> | This amount represents incremental declared dividends attributable to Noveprim noncontrolling interest holders who receive preferential dividends for fiscal year 2024. | This amount represents incremental declared dividends attributable to Noveprim noncontrolling interest holders who receive preferential dividends for fiscal year 2024. | This amount represents incremental declared dividends attributable to Noveprim noncontrolling interest holders who receive preferential dividends for fiscal year 2024. | This amount represents incremental declared dividends attributable to Noveprim noncontrolling interest holders who receive preferential dividends for fiscal year 2024. | This amount represents incremental declared dividends attributable to Noveprim noncontrolling interest holders who receive preferential dividends for fiscal year 2024. |
| <sup>(4)</sup> | This amount excludes non-GAAP adjustments attributable to noncontrolling interest holders. | This amount excludes non-GAAP adjustments attributable to noncontrolling interest holders. | This amount excludes non-GAAP adjustments attributable to noncontrolling interest holders. | This amount excludes non-GAAP adjustments attributable to noncontrolling interest holders. | This amount excludes non-GAAP adjustments attributable to noncontrolling interest holders. |
| <sup>(5)</sup> | The amount included in 2025 relates to a gain on the sale of a DSA site while the amount included in 2024 relates to a loss on the sale of a DSA site. | The amount included in 2025 relates to a gain on the sale of a DSA site while the amount included in 2024 relates to a loss on the sale of a DSA site. | The amount included in 2025 relates to a gain on the sale of a DSA site while the amount included in 2024 relates to a loss on the sale of a DSA site. | The amount included in 2025 relates to a gain on the sale of a DSA site while the amount included in 2024 relates to a loss on the sale of a DSA site. | The amount included in 2025 relates to a gain on the sale of a DSA site while the amount included in 2024 relates to a loss on the sale of a DSA site. |
| <sup>(6)</sup> | The amount included in 2025 relates to the derecognition of certain deferred tax assets due to the CDMO Gene Therapy intangible asset impairment charge. The amount included in 2024 relates to the recognition of deferred tax assets expected to be utilized as a result of changes to the Company's international financing structure. | The amount included in 2025 relates to the derecognition of certain deferred tax assets due to the CDMO Gene Therapy intangible asset impairment charge. The amount included in 2024 relates to the recognition of deferred tax assets expected to be utilized as a result of changes to the Company's international financing structure. | The amount included in 2025 relates to the derecognition of certain deferred tax assets due to the CDMO Gene Therapy intangible asset impairment charge. The amount included in 2024 relates to the recognition of deferred tax assets expected to be utilized as a result of changes to the Company's international financing structure. | The amount included in 2025 relates to the derecognition of certain deferred tax assets due to the CDMO Gene Therapy intangible asset impairment charge. The amount included in 2024 relates to the recognition of deferred tax assets expected to be utilized as a result of changes to the Company's international financing structure. | The amount included in 2025 relates to the derecognition of certain deferred tax assets due to the CDMO Gene Therapy intangible asset impairment charge. The amount included in 2024 relates to the recognition of deferred tax assets expected to be utilized as a result of changes to the Company's international financing structure. |
| <sup>(7)</sup> | Net loss available to Charles River Laboratories International, Inc. per common share excludes the effect of dilution and is computed using basic weighted-average number of shares outstanding for the three and twelve month periods ended December 27, 2025 and the three month period ended December 28, 2024. | Net loss available to Charles River Laboratories International, Inc. per common share excludes the effect of dilution and is computed using basic weighted-average number of shares outstanding for the three and twelve month periods ended December 27, 2025 and the three month period ended December 28, 2024. | Net loss available to Charles River Laboratories International, Inc. per common share excludes the effect of dilution and is computed using basic weighted-average number of shares outstanding for the three and twelve month periods ended December 27, 2025 and the three month period ended December 28, 2024. | Net loss available to Charles River Laboratories International, Inc. per common share excludes the effect of dilution and is computed using basic weighted-average number of shares outstanding for the three and twelve month periods ended December 27, 2025 and the three month period ended December 28, 2024. | Net loss available to Charles River Laboratories International, Inc. per common share excludes the effect of dilution and is computed using basic weighted-average number of shares outstanding for the three and twelve month periods ended December 27, 2025 and the three month period ended December 28, 2024. |

---

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** | **CHARLES RIVER LABORATORIES INTERNATIONAL, INC.** |
| | **SCHEDULE 6** | **SCHEDULE 6** | **SCHEDULE 6** | **SCHEDULE 6** | **SCHEDULE 6** |
| | **RECONCILIATION OF GAAP REVENUE GROWTH** | **RECONCILIATION OF GAAP REVENUE GROWTH** | **RECONCILIATION OF GAAP REVENUE GROWTH** | **RECONCILIATION OF GAAP REVENUE GROWTH** | **RECONCILIATION OF GAAP REVENUE GROWTH** |
| | **TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED)** <sup>(1)</sup> | **TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED)** <sup>(1)</sup> | **TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED)** <sup>(1)</sup> | **TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED)** <sup>(1)</sup> | **TO NON-GAAP REVENUE GROWTH, ORGANIC (UNAUDITED)** <sup>(1)</sup> |
| **Three Months Ended December 27, 2025** | **Three Months Ended December 27, 2025** | **Total CRL** | **RMS Segment** | **DSA Segment** | **MS Segment** |
| Revenue growth, reported | Revenue growth, reported | (0.8)% | 1.0% | (2.0)% | 0.7% |
| &nbsp;&nbsp;&nbsp;(Increase) decrease due to foreign exchange | &nbsp;&nbsp;&nbsp;(Increase) decrease due to foreign exchange | (1.9)% | (1.9)% | (1.5)% | (2.8)% |
| &nbsp;&nbsp;Impact of divestitures <sup>(2)</sup> | &nbsp;&nbsp;Impact of divestitures <sup>(2)</sup> | 0.1% | —% | 0.2% | —% |
| **Non-GAAP revenue growth, organic** <sup>(3)</sup> | **Non-GAAP revenue growth, organic** <sup>(3)</sup> | **(2.6)%** | **(0.9)%** | **(3.3)%** | **(2.1)%** |
| **Twelve Months Ended December 27, 2025** | **Twelve Months Ended December 27, 2025** | **Total CRL** | **RMS Segment** | **DSA Segment** | **MS Segment** |
| Revenue growth, reported | Revenue growth, reported | (0.9)% | 2.0% | (2.0)% | (0.4)% |
| &nbsp;&nbsp;&nbsp;(Increase) decrease due to foreign exchange | &nbsp;&nbsp;&nbsp;(Increase) decrease due to foreign exchange | (0.8)% | (0.8)% | (0.8)% | (1.2)% |
| &nbsp;&nbsp;Impact of divestitures <sup>(2)</sup> | &nbsp;&nbsp;Impact of divestitures <sup>(2)</sup> | 0.1% | —% | 0.2% | —% |
| **Non-GAAP revenue growth, organic** <sup>(3)</sup> | **Non-GAAP revenue growth, organic** <sup>(3)</sup> | **(1.6)%** | **1.2%** | **(2.6)%** | **(1.6)%** |
| <sup>(1)</sup> | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. | Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often-one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with U.S. GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance. |
| <sup>(2)</sup> | Impact of divestitures relates to the sale of a site within DSA. | Impact of divestitures relates to the sale of a site within DSA. | Impact of divestitures relates to the sale of a site within DSA. | Impact of divestitures relates to the sale of a site within DSA. | Impact of divestitures relates to the sale of a site within DSA. |
| <sup>(3)</sup> | Organic revenue growth is defined as reported revenue growth adjusted for divestitures and foreign exchange. | Organic revenue growth is defined as reported revenue growth adjusted for divestitures and foreign exchange. | Organic revenue growth is defined as reported revenue growth adjusted for divestitures and foreign exchange. | Organic revenue growth is defined as reported revenue growth adjusted for divestitures and foreign exchange. | Organic revenue growth is defined as reported revenue growth adjusted for divestitures and foreign exchange. |

---

<br>